Clinical Care Options Hepatitis - HCVThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6

277 records returned

Addition of Thymosin alpha-1 to Peginterferon alfa-2a Plus Ribavirin in Previous Nonresponder, Primarily Genotype 1 HCV Population Does Not Increase SVR Rate by Intent-to-Treat AnalysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Previous nonresponder HCV patients with undetectable HCV RNA at Week 24, and who complete 48-week treatment, may achieve higher SVR rates with addition of thymosin alpha-1 to peginterferon alfa-2a plus ribavirin vs addition of placebo. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 5, 2009 Category: Infectious Diseases Source Type: journals

PARADIGM: High-Dose Ribavirin Plus Peginterferon alfa-2a not Associated With Improved SVR Rate in HCV/HIV-Coinfected PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Higher SVR rates observed among HCV/HIV-coinfected patients achieving RVR or cEVR, regardless of the ribavirin dose. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 5, 2009 Category: Infectious Diseases Source Type: journals

Robust Antiviral Activity of NS5B Polymerase Inhibitor MK-3281 in Patients Infected With Genotype 1b HCV During 7-Day MonotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - In blinded safety analysis, headache, migraine, dizziness, tiredness, decreased libido, and abdominal pain were the most frequently reported adverse events. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 5, 2009 Category: Infectious Diseases Source Type: journals

Among HCV-Infected Patients With Poor Prognostic Indicators, Telaprevir-Based Therapy Significantly Improved Virologic Response vs Standard of CareEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Logistic regression analyses identified white race as prognostic for SVR (P = .02) and male sex as predictive of RVR (P = .04) among patients treated with the telaprevir-based regimen. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 5, 2009 Category: Infectious Diseases Source Type: journals

Patient and Graft Survival Lower Among HCV/HIV-Coinfected vs HCV-Monoinfected Liver Transplantation Recipients, but Incidence of Severe Posttransplantation Recurrence of HCV Disease SimilarEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - According to a multivariate analysis, independent predictors of graft loss in HIV/HCV-coinfected patients include low BMI, dual organ (kidney and liver) transplantation, HCV-positive donor, and treatment for acute rejection. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 4, 2009 Category: Infectious Diseases Source Type: journals

INFORM-1: First Interferon-Free Combination Therapy With Direct-Acting Antiviral Agents RG7128 and RG7227 Safe and Effective in Chronic Genotype 1 HCV PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - RG7128/RG7227 combination oral regimen well tolerated during 14 days of therapy in genotype 1 HCV treatment-naive and treatment-experienced patients. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 4, 2009 Category: Infectious Diseases Source Type: journals

Preliminary Data Suggest Virologic Benefit of Nitazoxanide Plus Peginterferon alfa-2a/Ribavirin in Cirrhotic Patients Infected With Genotype 1 HCV Who Failed Previous Peginterferon/Ribavirin TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - No serious adverse events occurred during combination therapy with nitazoxanide plus peginterferon alfa-2a/ribavirin in this pilot study. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 4, 2009 Category: Infectious Diseases Source Type: journals

Final Results of Study C208: High Rates of SVR Achieved With Telaprevir/Peginterferon/Ribavirin Combination Therapy in Treatment-Naive Patients With Chronic Genotype 1 HCV InfectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Sustained virologic response rates were similar for patients receiving telaprevir dosed every 8 hours vs every 12 hours. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 4, 2009 Category: Infectious Diseases Source Type: journals

NEXT-1: Adding Narlaprevir to Standard Peginterferon alfa-2b/Ribavirin Regimen Produces Rapid Virologic Response in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C InfectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - The adverse event profile of narlaprevir-based therapy was similar to peginterferon alfa-2b/ribavirin, but with a higher incidence of anemia and dizziness. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 3, 2009 Category: Infectious Diseases Source Type: journals

SILEN-C1: High Rate of Virologic Response at Weeks 4 and 12 With Addition of BI 201335 to Standard of Care for First-line Treatment of Genotype 1 HCV InfectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - The incidence of pruritus, jaundice, and rash was higher among patients treated with BI 201335–based combination therapy compared with patients receiving peginterferon alfa-2a/ribavirin alone. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 3, 2009 Category: Infectious Diseases Source Type: journals

Smoother Waters Ahead? New Directions in the Management of HCVEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - This downloadable slideset created by expert faculty provides insights into the magnitude of the HCV epidemic and current challenges when treating patients with HCV infection. The slides also review data from recent and ongoing clinical trials of STAT-C agents in late clinical development and their potential impact on HCV management. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 3, 2009 Category: Infectious Diseases Source Type: journals

PROVE 3: SVR Improved With Telaprevir Combined With Peginterferon alfa-2a/Ribavirin Therapy in Genotype 1 HCV Patients Failing Previous Regimen; 1-Year Durability DemonstratedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Response rates were significantly higher with telaprevir/peginterferon/ribavirin regimens vs peginterferon/ribavirin alone in previous nonresponders or relapsers to peginterferon/ribavirin treatment. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 2, 2009 Category: Infectious Diseases Source Type: journals

SPRINT-1: Up to 55% of Genotype 1 HCV Patients With Null Response After 4 Weeks of Peginterferon/Ribavirin Lead-in Achieved SVR With Triple-Therapy Regimen Containing BoceprevirEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Sustained virologic response rates were higher among Week 4 null responders who received subsequent 44 weeks of triple therapy with boceprevir relative to those who received only 24 weeks of triple therapy. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 2, 2009 Category: Infectious Diseases Source Type: journals

A2ALL Interim Analysis: Virologic Response 12 Weeks After Liver Transplantation Feasible With Pretransplantation Peginterferon alfa-2b/Ribavirin TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Although pre–liver transplantation peginterferon alfa-2b/ribavirin effectively prevented HCV recurrence posttransplantation in a subset of patients, serious adverse event rates were higher among patients who received peginterferon/ribavirin therapy prior to liver transplantation relative to patients who did not receive pretransplantation therapy. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - November 2, 2009 Category: Infectious Diseases Source Type: journals

Genetic Marker Strongly Associated With SVR to Peginterferon/Ribavirin in Patients With Genotype 1 HCVEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In this genomewide association study, a genetic polymorphism near IL28B, which encodes for interferon lambda-3, was found to strongly correlate with response to peginterferon/ribavirin in individuals infected with genotype 1 HCV. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 27, 2009 Category: Infectious Diseases Source Type: journals

IDEAL: Peginterferon alfa-2a and Peginterferon alfa-2b Regimens Demonstrate Comparable SVR EfficacyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In this large, randomized trial, SVR rates were similar among patients receiving low-dose peginterferon alfa-2b, standard-dose peginterferon alfa-2b, and standard-dose peginterferon alfa-2a, although differences in end-of-treatment response rates, relapse rates, and adverse events were noted. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 27, 2009 Category: Infectious Diseases Source Type: journals

Weight-Related Factors Associated With Risk for Liver Disease Progression According to Analysis of HALT-C DataEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In this analysis of the HALT-C study, insulin resistance, histologic features of fatty liver disease, and weight changes were found to be associated with increased rates of liver disease progression in patients with chronic hepatitis C. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 27, 2009 Category: Infectious Diseases Source Type: journals

Higher Total Cholesterol and Lower Oxidative Stress Biomarker Predict Rapid Virologic Response to Peginterferon/Ribavirin in HCV-Infected PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In a prospective study, younger age, non–genotype 1 HCV infection, higher baseline total cholesterol, and lower baseline 8-iso-prostaglandin F-2-alpha independently predicted rapid virologic response. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 21, 2009 Category: Infectious Diseases Source Type: journals

Standard-Duration HCV Treatment Superior to Individualized-Duration HCV Treatment Based on Time to HCV RNA Negativity by bDNA in Patients With Genotype 1 HCVEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In this prospective, randomized trial, the standard duration of 48 weeks with peginterferon/ribavirin was found to be superior to individualized treatment durations according to on-treatment response using a branched DNA assay for genotype 1 HCV patients; use of highly sensitive transcription-mediated amplification assay and consideration of baseline HCV RNA could result in higher response rates with individualized therapy. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 21, 2009 Category: Infectious Diseases Source Type: journals

Journal Options SlidesetEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In a prospective study, younger age, non–genotype 1 HCV infection, higher baseline total cholesterol, and lower baseline 8-iso-prostaglandin F-2-alpha independently predicted rapid virologic response. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 21, 2009 Category: Infectious Diseases Source Type: journals

Higher Total Cholesterol and Lower Oxidative Stress Biomarker Predict Rapid Virologic Response to Peginterferon/Ribavirin in HCV-Infected PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - In a prospective study, younger age, non–genotype 1 HCV infection, higher baseline total cholesterol, and lower baseline 8-iso-prostaglandin F-2-alpha independently predicted rapid virologic response. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 20, 2009 Category: Infectious Diseases Source Type: journals

Genetic Marker Strongly Associated With SVR to Peginterferon/Ribavirin in Patients With Genotype 1 HCVEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - In this genomewide association study, a genetic polymorphism near IL28B, which encodes for interferon lambda-3, was found to strongly correlate with response to peginterferon/ribavirin in individuals infected with genotype 1 HCV. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 20, 2009 Category: Infectious Diseases Source Type: journals

Standard-Duration HCV Treatment Superior to Individualized-Duration HCV Treatment Based on Time to HCV RNA Negativity by bDNA in Patients With Genotype 1 HCVEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - In this prospective, randomized trial, the standard duration of 48 weeks with peginterferon/ribavirin was found to be superior to individualized treatment durations according to on-treatment response using a branched DNA assay for genotype 1 HCV patients; use of highly sensitive transcription-mediated amplification assay and consideration of baseline HCV RNA could result in higher response rates with individualized therapy. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 15, 2009 Category: Infectious Diseases Source Type: journals

HCV Treatment Candidacy in an HCV/HIV-Coinfected Patient Receiving HIV TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - Norbert Bräu, MD, reviews the management of HCV in a patient coinfected with HIV. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 12, 2009 Category: Infectious Diseases Source Type: journals

HCV Treatment Candidacy in a HCV/HIV-Coinfected Patient Receiving HIV TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - Norbert Bräu, MD, reviews the management of HCV in a patient coinfected with HIV. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 12, 2009 Category: Infectious Diseases Source Type: journals

IDEAL: Peginterferon alfa-2a and Peginterferon alfa-2b Regimens Demonstrate Comparable SVR EfficacyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - In this large, randomized trial, SVR rates were similar among patients receiving low-dose peginterferon alfa-2b, standard-dose peginterferon alfa-2b, and standard-dose peginterferon alfa-2a, although differences in end-of-treatment response rates, relapse rates, and adverse events were noted. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 12, 2009 Category: Infectious Diseases Source Type: journals

Management and Treatment of Special Populations of HCV-Infected PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In this downloadable slideset, Ira M. Jacobson, MD, reviews the AASLD guideline recommendations for the treatment of special populations of HCV-infected persons. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 6, 2009 Category: Infectious Diseases Source Type: journals

Initial HCV Therapy in a Patient With Mild DepressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - Join K. Rajender Reddy, MD, in choosing the optimal treatment strategies for a patient with chronic HCV infection and a history of depression. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - October 6, 2009 Category: Infectious Diseases Source Type: journals

Weight-Related Factors Associated With Risk for Liver Disease Progression According to Analysis of HALT-C DataEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - In this analysis of the HALT-C study, insulin resistance, histologic features of fatty liver disease, and weight changes were found to be associated with increased rates of liver disease progression in patients with chronic hepatitis C. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - September 30, 2009 Category: Infectious Diseases Source Type: journals

Initial HCV Management, Treatment and MonitoringEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Virtual Presentation - John McHutchison, MD, FRACP, provides an overview of the AASLD 2009 guideline update on the initial management, treatment, and monitoring of patients with hepatitis C. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - September 11, 2009 Category: Infectious Diseases Source Type: journals

Management of a Genotype 1 HCV Patient in a Methadone Maintenance ProgramEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - David R. Nelson, MD, discusses management strategies and AASLD recommendations involved in managing a treatment-naive genotype 1 HCV–infected patient who is participating in a methadone maintenance program (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - September 11, 2009 Category: Infectious Diseases Source Type: journals

Initial HCV Management, Treatment and MonitoringEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In this downloadable slideset, John G. McHutchison, MD, FRACP, provides an update on the initial management, treatment, and monitoring of patients with hepatitis C. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - September 11, 2009 Category: Infectious Diseases Source Type: journals

Management of an HCV-Infected Compensated Cirrhotic Patient With Moderate Alcohol UseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - Guy Neff, MD, MBA, discusses the challenging management decisions involved in treating an HCV-infected compensated cirrhotic patient with moderate alcohol use. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - September 11, 2009 Category: Infectious Diseases Source Type: journals

Management and Treatment of Special Populations of HCV-Infected PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Virtual Presentation - Ira M. Jacobson, MD, reviews the AASLD guideline recommendations for the treatment of special populations of HCV-infected persons. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - September 11, 2009 Category: Infectious Diseases Source Type: journals

Management of an Genotype 1 HCV Patient in a Methadone Maintenance ProgramEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - David R. Nelson, MD, discusses management strategies and AASLD recommendations involved in managing a treatment-naive genotype 1 HCV–infected patient who is participating in a methadone maintenance program (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - September 11, 2009 Category: Infectious Diseases Source Type: journals

Management of an HCV-Infected Black Woman With Delayed Diagnosis and TreatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - Maribel Rodriguez-Torres, MD, CPI, discusses the management of an HCV-infected black woman with significant liver disease due to delayed diagnosis and treatment. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - September 11, 2009 Category: Infectious Diseases Source Type: journals

Hepatitis Annual Update 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Review the latest data on HBV and HCV management, as well as the diagnosis and management of decompensated cirrhosis. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - August 7, 2009 Category: Infectious Diseases Source Type: journals

Update on Investigational HCV AgentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Jean-Michel Pawlotsky, MD, PhD, discusses how insights into the virology of HCV have unraveled several targets for potential novel therapeutics. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - July 23, 2009 Category: Infectious Diseases Source Type: journals

Mechanisms of Response and Nonresponse to HCV TreatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Raymond T. Chung, MD, reviews the mechanisms of response and nonresponse in HCV treatment, including fixed and modifiable factors. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - July 16, 2009 Category: Infectious Diseases Source Type: journals

Hepatitis C Testing and Counseling: the Gateway to TreatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Virtual Presentation - David L. Thomas, MD, MPH, discusses how risk-based testing can help identify the large population of undiagnosed patients infected with hepatitis C. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - July 9, 2009 Category: Infectious Diseases Source Type: journals

Hepatitis C Testing and Counseling: the Gateway to TreatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In this downloadable slideset, David L. Thomas, MD, MPH, discusses the importance of hepatitis C virus testing, as it is the first step in the management and treatment of HCV infection. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - July 9, 2009 Category: Infectious Diseases Source Type: journals

Update on the Management of HCV and the Complications of Liver DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Join Adrian M. Di Bisceglie, MD, FACP; Michael P. Manns, MD; and Stefan Zeuzem, MD, as they discuss the most clinically relevant new data presented at 2009 EASL regarding the treatment of HCV infection and the management of complications associated with advanced liver disease. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - June 16, 2009 Category: Infectious Diseases Source Type: journals

2009 HCV Advanced Practice Curriculum: Fibrosis and Disease Progression in HCVEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Virtual Presentation - Raymond T. Chung, MD, reviews complications of advanced liver disease, how to assess the severity of liver disease, and how treatment may address these complications. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - June 12, 2009 Category: Infectious Diseases Source Type: journals

Fibrosis and Disease Progression in HCVEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In this downloadable slideset, Raymond T. Chung, MD, reviews the complications associated with advanced liver disease, how to assess the severity of liver disease, and how treatment may affect outcomes. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - June 12, 2009 Category: Infectious Diseases Source Type: journals

PROVE 1: Combination of Telaprevir With Peginterferon/Ribavirin Significantly Increases SVR in Treatment-Naive Patients With HCV Genotype 1Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In a randomized, placebo-controlled trial, the coadministration of telaprevir with peginterferon/ribavirin therapy allowed for a reduced duration of therapy from 48 weeks to 24 weeks without compromising SVR rates. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - May 29, 2009 Category: Infectious Diseases Source Type: journals

PROVE 1: Combination of Telaprevir With Peginterferon/Ribavirin Significantly Increases SVR in Treatment-Naive Patients With HCV Genotype 1Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - In a randomized, placebo-controlled trial, the coadministration of telaprevir with peginterferon/ribavirin therapy allowed for a reduced duration of therapy from 48 weeks to 24 weeks without compromising SVR rates. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - May 28, 2009 Category: Infectious Diseases Source Type: journals

2009 HCV Advanced Practice Curriculum: Current Management of HCV Treatment-Experienced PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Virtual Presentation - Maria H. Sjogren, MD, MPH, FACP, discusses current management options for HCV-infected, treatment-experienced patients. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - May 15, 2009 Category: Infectious Diseases Source Type: journals

Current Management of HCV Treatment-Experienced PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In this downloadable slideset, Maria H. Sjogren, MD, discusses the rationale for retreating HCV nonresponders and explores treatment options for this subset of patients. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - May 15, 2009 Category: Infectious Diseases Source Type: journals

HALT-C: Long-term Maintenance Peginterferon alfa-2a Not Associated With Reduced Disease Progression Rates in Prior Nonresponders With Advanced Chronic HCV InfectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In a randomized, prospective trial, maintenance therapy with low-dose peginterferon alfa-2a 90 µg/week did not decrease the rate of clinical or histologic disease progression, incidence of hepatocellular carcinoma, or adverse events vs untreated patients. (Source: Clinical Care Options Hepatitis - HCV)
Source: Clinical Care Options Hepatitis - HCV - May 6, 2009 Category: Infectious Diseases Source Type: journals